Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01) Study of Continuous REVLIMIDÂ® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH